Background Factor Xa inhibitors and vitamin K antagonists (VKAs) are now recommended in
treatment guidelines for preventing stroke and systemic embolic events in people with atrial …

Background and Purpose—This ARISTOPHANES study (Anticoagulants for Reduction in
Stroke: Observational Pooled Analysis on Health Outcomes and Experience of Patients) …

The PRISMA statement is a reporting guideline designed to improve the completeness of
reporting of systematic reviews and meta-analyses. Authors have used this guideline …

Abstract Background Originator trastuzumab (Herceptin®; H) is an antibody-targeted therapy
to treat patients with human epidermal growth factor receptor 2-positive (HER2+) early …

Background Stroke is the most serious clinical consequence of atrial fibrillation, which is the
most common cardiac arrhythmia. Non-vitamin K antagonist oral anticoagulants (NOACs) …

Background: Whether dabigatran is associated with a lower risk of acute kidney injury (AKI)
in patients with nonvalvular atrial fibrillation (NVAF) remains unknown. Objectives: The …

Background The goal of this study was to compare the safety and effectiveness of individual
antiembolic interventions in nonvalvular atrial fibrillation (AF): novel oral anticoagulants …

Aims: The aim of this study was to investigate the prognosis in patients with atrial fibrillation
(AF) and intracerebral haemorrhage (ICH) having a left atrial appendage occlusion (LAAO) …

Background Patients with diabetes who had a recent myocardial infarction (MI) are at high
risk of cardiovascular events. Therefore, risk assessment is important for treatment and …

Abstract Background Direct oral anticoagulants (DOACs) are indicated for the prevention of
stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation. While no …